• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估耐多药和广泛耐药结核病患者的生活质量。

Assessing quality of life for multidrug-resistant and extensively drug-resistant tuberculosis patients.

作者信息

Vo Nam Xuan, Xuan Doan Thy Bui, Kha Vo Di Ngoc, Tran Tu Kim, Vo Trung Quang

机构信息

Graduate Program in Social, Economic and Administrative Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand.

Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam.

出版信息

J Pak Med Assoc. 2019 Jun;69(Suppl 2)(6):S137-S157.

PMID:31369544
Abstract

OBJECTIVE

One can hypothesize that Mycobacterium genus originated more than 150 million years ago and has evolved to become one of the leading lethal infectious diseases. Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) patients are directly affected by the disease and other subjective issues, such as related diseases, medical costs and social issues, which all have negative impacts on patient quality of life (QOL). Our purpose is to define the status of health-related QOL for international MDR-TB and XDR-TB patients.

METHODS

Systematic review is a good method for searching and selecting related researches and articles. As such, we have searched for and cited related articles on reputable databases, such as PubMed, Cochrance, and Google Scholar. A data overview was performed to draw conclusions and results on the QOL of MDR-TB and XDR-TB patients.

RESULTS

A total of 18 articles were included, using instruments from the World Health Organization, Euroqol, Short Form, AQ and the Seattle Obstructive Lung Disease Questionnaire. The QOL of MDR-TB and XDR-TB patients was found to be compromised due to the strong resistance of Mycobacterium tuberculosis, economic pressure and community alienation.

CONCLUSIONS

A number of QOL and health-related QOL studies on MDR-TB and XDR-TB patients are limited, especially with XDR-TB patients. Significant numbers of MDR-TB and XDR-TB patients still have sequelae after completing treatment, reducing the health-related QOL among these patients.

摘要

目的

可以推测分枝杆菌属起源于1.5亿多年前,并已演变成主要的致命传染病之一。耐多药结核病(MDR-TB)和广泛耐药结核病(XDR-TB)患者直接受到该疾病以及其他主观问题的影响,如相关疾病、医疗费用和社会问题,所有这些都对患者的生活质量(QOL)产生负面影响。我们的目的是确定国际MDR-TB和XDR-TB患者与健康相关的生活质量状况。

方法

系统评价是搜索和选择相关研究及文章的好方法。因此,我们在知名数据库,如PubMed、Cochrance和谷歌学术上搜索并引用了相关文章。进行了数据概述,以得出关于MDR-TB和XDR-TB患者生活质量的结论和结果。

结果

共纳入18篇文章,使用了世界卫生组织、欧洲五维度健康量表、简明健康调查问卷、AQ量表和西雅图阻塞性肺病问卷等工具。发现MDR-TB和XDR-TB患者的生活质量因结核分枝杆菌的强耐药性、经济压力和社区疏离感而受到损害。

结论

关于MDR-TB和XDR-TB患者的生活质量及与健康相关的生活质量的研究数量有限,尤其是XDR-TB患者。大量MDR-TB和XDR-TB患者在完成治疗后仍有后遗症,降低了这些患者与健康相关的生活质量。

相似文献

1
Assessing quality of life for multidrug-resistant and extensively drug-resistant tuberculosis patients.评估耐多药和广泛耐药结核病患者的生活质量。
J Pak Med Assoc. 2019 Jun;69(Suppl 2)(6):S137-S157.
2
A cross-sectional study about knowledge and attitudes toward multidrug-resistant and extensively drug-resistant tuberculosis in a high-burden drug-resistant country.在一个高耐药负担国家开展的关于耐多药和广泛耐药结核病知识与态度的横断面研究。
Int J Mycobacteriol. 2016 Jun;5(2):128-34. doi: 10.1016/j.ijmyco.2015.12.004. Epub 2016 Feb 18.
3
Cost-effectiveness of treating multidrug- and extensively drug-resistant tuberculosis: A systematic review.
J Pak Med Assoc. 2019 Jun;69(Suppl 2)(6):S131-S136.
4
Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.抗击广泛耐药结核病计划:联邦结核病特别工作组的建议
MMWR Recomm Rep. 2009 Feb 13;58(RR-3):1-43.
5
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.欧洲耐多药/广泛耐药结核病患者的管理:一份欧洲结核病研究和培训网络(TBNET)共识声明
Eur Respir J. 2014 Jul;44(1):23-63. doi: 10.1183/09031936.00188313. Epub 2014 Mar 23.
6
Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China.中国一家三级结核病防治医院中耐多药和广泛耐药结核病的基因分型和临床特征。
BMC Infect Dis. 2013 Jul 12;13:315. doi: 10.1186/1471-2334-13-315.
7
Palliative care and symptom relief for people affected by multidrug-resistant tuberculosis.耐多药结核病患者的姑息治疗和症状缓解。
Int J Tuberc Lung Dis. 2019 Aug 1;23(8):881-890. doi: 10.5588/ijtld.18.0428.
8
Predictors of multidrug- and extensively drug-resistant tuberculosis in a high HIV prevalence community.高 HIV 流行地区耐多药和广泛耐药结核病的预测因素。
PLoS One. 2010 Dec 29;5(12):e15735. doi: 10.1371/journal.pone.0015735.
9
Cost of multi drug resistance tuberculosis in Germany.德国耐多药结核病的成本。
Respir Med. 2014 Nov;108(11):1677-87. doi: 10.1016/j.rmed.2014.09.021. Epub 2014 Oct 15.
10
The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia.埃塞俄比亚阿姆哈拉地区耐多药结核病患者中广泛耐药前和广泛耐药结核病的负担。
PLoS One. 2020 Feb 13;15(2):e0229040. doi: 10.1371/journal.pone.0229040. eCollection 2020.

引用本文的文献

1
The effects of stigma and social support on the health-related quality of life of people with drug resistance tuberculosis in Lagos, Nigeria.耻辱感和社会支持对尼日利亚拉各斯耐多药结核病患者健康相关生活质量的影响。
Qual Life Res. 2025 May;34(5):1305-1316. doi: 10.1007/s11136-025-03902-5. Epub 2025 Feb 18.
2
Assessing the quality of life in patients with drug-resistant tuberculosis: a cross-sectional study.评估耐多药结核病患者的生活质量:一项横断面研究。
BMC Pulm Med. 2024 Jun 27;24(1):303. doi: 10.1186/s12890-024-03119-1.
3
Health-Related Quality of Life (HRQoL) of Patients with Tuberculosis: A Review.
结核病患者的健康相关生活质量:综述
Infect Dis Rep. 2022 Jul 18;14(4):509-524. doi: 10.3390/idr14040055.
4
Application of KTH-integrated nursing model in care of patients with multi-drug resistant tuberculosis.KTH综合护理模式在耐多药肺结核患者护理中的应用
Am J Transl Res. 2021 Jun 15;13(6):6855-6863. eCollection 2021.
5
Quality of life with tuberculosis.结核病患者的生活质量
J Clin Tuberc Other Mycobact Dis. 2019 Sep 20;17:100121. doi: 10.1016/j.jctube.2019.100121. eCollection 2019 Dec.